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OBJECTIVE: Diabetic peripheral neuropathy (DPN) is a debili-
tating complication of diabetes and causes sensory symptoms
that impact health and functionality. The purpose of this study
was to test the hypothesis that there was a direct association
between the symptoms associated with DPN (SDPN), as mea-
sured by a new instrument the Neuropathy Total Symptom Score
(NTSS-6 [self administered]), and health-related utility as mea-
sured by the EQ5Dindex. The NTSS-6 provides a score of 0 to 3.66
in each of six domains. The score (range 0 to 21.96) is simply
summed with zero meaning no symptoms. METHODS: A postal
survey using various instruments including the NTSS-6 and the
EQ5D was mailed to subjects identiﬁed at random as having
either type-1 or Type-2 diabetes using the same methods as the
Health Outcomes Data Repository (HODaR). Univariate and
multivariate analysis were applied. This is a preliminary analy-
sis of the ﬁrst 604 returns. RESULTS: The mean age of respon-
dents was 64 years (IQR 55–73); 58% were male and the mean
duration of diabetes was 14 years (IQR 5–18). Of the 604
patients, 24% reported having no neuropathic symptoms. The
overall mean (SD) EQ5Dindex was 0.65 (0.33), and mean NTSS-
6 score 6.2 (median and IQR 4.33, 1.0–10.33). In univariate
analysis there was a direct association between the two instru-
ments (correlation coefﬁcient 0.57). Modeling the EQ5Dindex in
multiple linear regression analysis to account for confounding,
the NTSS-6 score was found to remain directly associated with
utility, whereby an increase of one unit on the NTSS-6 resulted
in as reduction in the EQ5Dindex of 0.029 units (p < 0.001). 
CONCLUSIONS: SDPN, as measured by the NTSS-6, were
directly associated with health-related utility. After accounting
for confounding factors, a unit change in the NTSS-6 was equiv-
alent to a change in utility that is considered to be clinically
meaningful.
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OBJECTIVE: To develop self-report questionnaires for physician
use in the evaluation of diabetic patient reluctance to start or
step up insulin regimens. METHODS: An Advisory Committee
(AC) was set up. It consisted of 3 diabetes specialists/endocri-
nologists, 1 behavioural psychiatrist and 2 general practitioners.
Three patient focus groups were formed from a pool of 23 type-
1 and 2 diabetic patients. Interviewees were asked to list fears,
constraints and beneﬁts associated with insulinization, injection
and insulin regimen step-up. After analysis of the focus groups,
a list of detailed concepts and two test questionnaires were devel-
oped and independently validated by the AC with content valid-
ity being assessed on 16 type-1 and 2 diabetic patients. Patients
completed the questionnaires before being systematically asked
to comment on the questionnaire as a whole and more speciﬁ-
cally on each element of the questionnaire. Questionnaires were
then redrafted and tested on 16 other patients. After analysis of
patient tests, a revised questionnaire was produced and validated
by the AC. RESULTS: Eleven elements (Insulinization: symbolic,
fears, constraints, beneﬁts, product physical characteristics.
Injection: symbolic, fears, constraints, positive points. Insulin
regimen intensiﬁcation: symbolic, fears) and 31 detailed concepts
were identiﬁed using the patient focus groups. Each test ques-
tionnaire contained 22 items (20 relating to insulin regimen start
or insulin regimen step-up plus 2 relating to inhaled insulin).
After initial cognitive debrieﬁng, one item was added, taking
each questionnaire to 23 items and response choices were 
signiﬁcantly modiﬁed in both questionnaires by the AC. After
second cognitive debrieﬁng 2 items were excluded from both
questionnaires by the AC. The pilot questionnaires therefore
included 21 items. CONCLUSION: These pilot questionnaires
may help physicians to assess the hurdles faced by diabetic
patients in starting or stepping up insulin regimens. The ques-
tionnaires are now undergoing item reduction, scoring and 
validation in two case-report studies.
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OBJECTIVE: To develop and evaluate a self-report clinical and
research adherence barrier survey designed to screen for speciﬁc
barriers to adherence across a spectrum of chronic conditions.
METHODS: Item generation and domain structures were based
on literature and expert opinion. Interviews with 33 patients
with asthma, diabetes, and heart failure were used to develop 47
Likert-type items. These were tested on the Web with 605
patients with asthma, diabetes, and depression. Factor analysis
was performed to identify conceptually similar item groupings;
and item validity in relation to a self-reported measure of adher-
ence, the distribution of item responses, and factor structure
were studied to select ﬁnal survey items. RESULTS: Twenty items
were retained based on correlation with validity criteria and clin-
ical relevance in the following domains: Lifestyle, Attitudes and
Beliefs, Help from Others, Talking with Health care Team, and
Difﬁculty Taking Medicines. A post hoc cut point dichotomizing
responses into “present” and “absent” was selected for each
item. The Barrier Total Index (BTI), the number of “barrier-
present” items, had an observed range from 0 to 18, a mean of
4.2 (±3.4), and good reliability (Cronbach’s alpha = 0.77). The
validity of the BTI with a self-report of a missed dose of medi-
cine in the past week was excellent. Patients who “missed” had
a mean of 6 barriers vs. 2.6 for those who did not (p < 0.0001).
CONCLUSION: The ASK Adherence Barrier Survey appears 
to be a useful tool to identify barriers to adherence in chronic
diseases. The survey can facilitate discussion of adherence 
and identify opportunities to implement barrier-speciﬁc 
interventions.
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Patient knowledge on own disease is recognised as key factor to
reach therapeutical goals. OBIECTIVE: To develop a question-
naire exploring patient preference on SBGM systems; to measure
patient satisfaction on medical information delivered by the hos-
pital health care personnel. METHODS: 454 NIDDM patients,
